Form 4: Immunovant Director Acquires Shares and Options

Immunovant, Inc. Director Robert Graham Susman acquired restricted stock units and stock options, reflecting a significant stake in the company's future.

Summary

• Robert Graham Susman, a Director at Immunovant, Inc., acquired 13,880 shares of common stock on April 7, 2026, valued at $0.
• These shares were acquired as restricted stock units (RSUs) granted under the company's 2019 Equity Incentive Plan.
• The RSUs are set to vest in full on April 1, 2027, contingent upon Susman's continued service to Immunovant.
• Additionally, Susman acquired stock options to purchase 7,061 shares of common stock at an exercise price of $24.61.
• These options also vest on April 1, 2027, subject to continued service.
• Following these transactions, Susman beneficially owns 38,896 shares of common stock.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive filing, as it reflects standard executive compensation practices and an alignment of director interests with the company's long-term success.

Positives

• Director Robert Graham Susman has increased his beneficial ownership through the acquisition of RSUs and stock options, indicating confidence in the company's prospects.
• The acquisition of RSUs and options, which vest in the future, aligns the director's interests with long-term shareholder value.
• The grant of equity incentives suggests a commitment to retaining key leadership personnel.

Negatives

• The acquisition of RSUs and options at $0 and an exercise price of $24.61 respectively, does not represent an immediate cash outlay by the director, but rather a future potential gain.
• The filing does not provide details on the total value of the RSUs or options granted, making it difficult to assess the full financial impact on the director.

Risks

• The vesting of RSUs and stock options is contingent on the Reporting Person's continuous service to the Issuer, meaning any departure before April 1, 2027, would result in forfeiture.
• The stock options have an exercise price of $24.61, meaning they will only be profitable if the stock price exceeds this level by April 1, 2036.

Future Outlook

The vesting of restricted stock units and stock options on April 1, 2027, is a key future event, contingent on the director's continued service. The stock options are exercisable until April 1, 2036.

Industry Context

StockSavvy.ai notes that the issuance of equity incentives like RSUs and stock options to directors is a common practice in the biotechnology and pharmaceutical sectors to align executive interests with long-term company performance and shareholder value.

Stakeholder Impact

• Shareholders: The alignment of director incentives with long-term company performance can be viewed positively.
• Employees: The company's use of equity incentives may indicate a broader compensation strategy that could extend to other employees.
• Management: The grant of equity reinforces the importance of retaining key leadership.

Next Steps

• Continued service by Robert Graham Susman until April 1, 2027, for RSUs and stock options to vest.
• Potential exercise of stock options by Robert Graham Susman between April 1, 2027, and April 1, 2036.

Key Dates

Keywords

Immunovant, IMVT, Form 4, SEC Filing, Insider Trading, Stock Options, Restricted Stock Units, Equity Incentive Plan, Director Compensation, Beneficial Ownership